GURUFOCUS.COM » STOCK LIST » Basic Materials » Agriculture » Huapont Life Science Co Ltd (SZSE:002004) » Definitions » Operating Income

Huapont Life Science Co (SZSE:002004) Operating Income : ¥1,395 Mil (TTM As of Mar. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Huapont Life Science Co Operating Income?

Huapont Life Science Co's Operating Income for the three months ended in Mar. 2024 was ¥353 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 was ¥1,395 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Huapont Life Science Co's Operating Income for the three months ended in Mar. 2024 was ¥353 Mil. Huapont Life Science Co's Revenue for the three months ended in Mar. 2024 was ¥2,915 Mil. Therefore, Huapont Life Science Co's Operating Margin % for the quarter that ended in Mar. 2024 was 12.12%.

Warning Sign:

Huapont Life Science Co Ltd operating margin has been in a 5-year decline. The average rate of decline per year is -1.2%.

Huapont Life Science Co's 5-Year average Growth Rate for Operating Margin % was -1.20% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Huapont Life Science Co's annualized ROC % for the quarter that ended in Mar. 2024 was 4.14%. Huapont Life Science Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 13.23%.


Huapont Life Science Co Operating Income Historical Data

The historical data trend for Huapont Life Science Co's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Huapont Life Science Co Operating Income Chart

Huapont Life Science Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,587.95 1,558.33 1,618.86 2,008.25 1,502.89

Huapont Life Science Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 461.02 421.91 347.29 272.68 353.23

Huapont Life Science Co Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1,395 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Huapont Life Science Co  (SZSE:002004) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Huapont Life Science Co's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=1412.904 * ( 1 - 24.38% )/( (25264.834 + 26290.205)/ 2 )
=1068.4380048/25777.5195
=4.14 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=30727.397 - 4708.915 - ( 4413.135 - max(0, 10633.752 - 11387.4+4413.135))
=25264.834

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=31479.044 - 4316.595 - ( 4901.933 - max(0, 11278.182 - 12150.426+4901.933))
=26290.205

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Huapont Life Science Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=1483.22/( ( (10024.471 + max(807.906, 0)) + (10025.532 + max(1566.134, 0)) )/ 2 )
=1483.22/( ( 10832.377 + 11591.666 )/ 2 )
=1483.22/11212.0215
=13.23 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1502.404 + 2674.606 + 1570.893) - (4708.915 + 0 + 231.082)
=807.906

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1947.18 + 2507.214 + 1595.767) - (4316.595 + 0 + 167.432)
=1566.134

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Huapont Life Science Co's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as:

Operating Margin %=Operating Income (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=353.226/2915.49
=12.12 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Huapont Life Science Co Operating Income Related Terms

Thank you for viewing the detailed overview of Huapont Life Science Co's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Huapont Life Science Co (SZSE:002004) Business Description

Traded in Other Exchanges
N/A
Address
No. 69, Renhe Xingguang Avenue, Yubei District, Chongqing, CHN, 401121
Huapont Life Science Co Ltd is a China-based company engaged in the manufacturing and distribution of pharmaceutical products. In addition, the company is also engaged in the agrochemical business and medical business. The agrochemical department is mainly engaged in the research and development, production, sales, and technical services of pesticide intermediates, original drugs, and preparations.
Executives
Zhang Hai An Directors, executives
Wang Rong Director
Yu Jun Tian Director
Zhang Song Shan Directors, executives
Chen Zhi Securities Affairs Representative
Jiang Kang Wei Director
Lv Li Ming Director
Li Sheng Xue Director
Luo Da Lin Supervisors
Li Zhi Directors, executives
Tian Song Min Executives
Wu Bi Zhong Director
Yu Yun Jian Supervisors
Gu Chuan Wei Supervisors

Huapont Life Science Co (SZSE:002004) Headlines

No Headlines